Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Business partnership

CDT Equity QIMA Tapinarof Skin Partnership

Analysis based on 7 articles · First reported Sep 18, 2026 · Last updated Sep 18, 2026

Sentiment
-5
Attention
2
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The partnership is a small-cap biotech research collaboration with no near-term revenue, so its market impact is limited to Equity Group shares, which fell sharply in pre-market trading. Broader market effects are negligible, though it highlights continued interest in autoimmune dermatology assets and the contract research sector.

biotechnology pharmaceuticals contract research

Equity Group (Nasdaq: CDT) announced on September 18, 2026 that it has entered into a partnership with QIMA Life Sciences, a French contract research organization specializing in preclinical dermatology, to explore several of CDT's assets in autoimmune skin diseases. The collaboration will leverage QIMA's access to human skin from healthy donors and patients, providing clinically relevant data intended to accelerate translation to the clinic and give potential license partners confidence. Initial studies will center on tapinarof, marketed as VTAMA, which is approved for plaque psoriasis and atopic dermatitis in the United States and Japan. CDT holds an intellectual property portfolio around tapinarof, including solid form and method-of-use patents in combination with other drugs, and QIMA will test these novel combinations in psoriatic patient skin with the goal of developing a second-generation tapinarof product with greater efficacy and patient benefit. CDT also plans to investigate its proprietary tapinarof combinations in vitiligo, a chronic autoimmune disorder affecting approximately 0.5% to 2.0% of the global population. The global vitiligo drug market was estimated at about $2.6 billion in 2025 and is projected to reach $6.6 billion by 2030. Despite the announcement, CDT shares fell in pre-market Nasdaq trading, reportedly down 9.23 percent to $0.1720 after closing the prior session 4.29 percent lower.

90 Equity Group entered partnership QIMA Life Sciences
70 QIMA Life Sciences agreed to test Equity Group
60 Equity Group shares fell
priv
Equity Group is the central party, entering a partnership with QIMA Life Sciences to advance its tapinarof assets in autoimmune skin diseases. The announcement did not reassure investors, as its shares reportedly fell 9.23 percent in pre-market Nasdaq trading.
Importance 95.0 Sentiment -20.0
priv
QIMA Life Sciences is the contract research partner providing access to human skin tissue and preclinical dermatology expertise. The collaboration expands its pipeline of pharma and biotech partnerships, a modest positive for its business.
Importance 70.0 Sentiment 10.0
exch
Nasdaq is the exchange where Equity Group shares trade and where the reported pre-market decline occurred. The event has no material effect on the exchange itself.
Importance 10.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.